JP2005522476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005522476A5 JP2005522476A5 JP2003582114A JP2003582114A JP2005522476A5 JP 2005522476 A5 JP2005522476 A5 JP 2005522476A5 JP 2003582114 A JP2003582114 A JP 2003582114A JP 2003582114 A JP2003582114 A JP 2003582114A JP 2005522476 A5 JP2005522476 A5 JP 2005522476A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- indan
- dibromo
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 208000017520 skin disease Diseases 0.000 claims 12
- 208000019423 liver disease Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 7
- 206010020850 Hyperthyroidism Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 206010020112 Hirsutism Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 208000006454 hepatitis Diseases 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000005057 thyrotoxicosis Diseases 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 208000001348 Chloracne Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 208000002260 Keloid Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 108700005075 Regulator Genes Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 231100000354 acute hepatitis Toxicity 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 210000001117 keloid Anatomy 0.000 claims 2
- 201000011486 lichen planus Diseases 0.000 claims 2
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- -1 pyridin-2-yl-methoxy Chemical group 0.000 claims 2
- 239000005495 thyroid hormone Substances 0.000 claims 2
- 229940036555 thyroid hormone Drugs 0.000 claims 2
- 208000003663 ventricular fibrillation Diseases 0.000 claims 2
- 206010047302 ventricular tachycardia Diseases 0.000 claims 2
- QBMQWMRXNWTLCF-UHFFFAOYSA-N 2-[4,6-dibromo-5-[3-propan-2-yl-4-[(5-thiophen-3-yl-1,2,4-oxadiazol-3-yl)methoxy]phenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC(N=1)=NOC=1C=1C=CSC=1 QBMQWMRXNWTLCF-UHFFFAOYSA-N 0.000 claims 1
- IBAOSHKSGPSIPT-UHFFFAOYSA-N 2-[4,6-dibromo-5-[4-(naphthalen-2-ylmethoxy)-3-propan-2-ylphenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound C1=CC=CC2=CC(COC3=CC=C(OC=4C(=C5CCC(CC(O)=O)C5=CC=4Br)Br)C=C3C(C)C)=CC=C21 IBAOSHKSGPSIPT-UHFFFAOYSA-N 0.000 claims 1
- UKVKVVBZGUXQFX-UHFFFAOYSA-N 2-[4,6-dibromo-5-[4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-3-propan-2-ylphenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC=1C(C)=NOC=1C UKVKVVBZGUXQFX-UHFFFAOYSA-N 0.000 claims 1
- GAJSOXNPNODZNA-UHFFFAOYSA-N 2-[4,6-dibromo-5-[4-[(4-fluorophenyl)methoxy]-3-propan-2-ylphenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC1=CC=C(F)C=C1 GAJSOXNPNODZNA-UHFFFAOYSA-N 0.000 claims 1
- GKUPMCWFIBTWPA-UHFFFAOYSA-N 2-[4,6-dibromo-5-[4-[(5-methyl-1,2-oxazol-3-yl)methoxy]-3-propan-2-ylphenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC=1C=C(C)ON=1 GKUPMCWFIBTWPA-UHFFFAOYSA-N 0.000 claims 1
- OCIODFSKYHFPIE-UHFFFAOYSA-N 2-[4,6-dibromo-5-[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]-3-propan-2-ylphenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC(=C(O1)C)N=C1C1=CC=CC=C1 OCIODFSKYHFPIE-UHFFFAOYSA-N 0.000 claims 1
- SJQCYYMHFWVSJH-UHFFFAOYSA-N 2-[5-[4-[(4-amino-6-anilino-1,3,5-triazin-2-yl)methoxy]-3-propan-2-ylphenoxy]-4,6-dibromo-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC(N=1)=NC(N)=NC=1NC1=CC=CC=C1 SJQCYYMHFWVSJH-UHFFFAOYSA-N 0.000 claims 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 1
- UBMWERFQWJYCPE-UHFFFAOYSA-N 4-[[4-[[4,6-dibromo-1-(carboxymethyl)-2,3-dihydro-1h-inden-5-yl]oxy]-2-propan-2-ylphenoxy]methyl]benzoic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC1=CC=C(C(O)=O)C=C1 UBMWERFQWJYCPE-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 206010037083 Prurigo Diseases 0.000 claims 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 229930003316 Vitamin D Chemical class 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000005108 alkenylthio group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000005109 alkynylthio group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 claims 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- CGJMROBVSBIBKP-UHFFFAOYSA-N malonamic acid Chemical compound NC(=O)CC(O)=O CGJMROBVSBIBKP-UHFFFAOYSA-N 0.000 claims 1
- 230000003818 metabolic dysfunction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Chemical class 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0208384.8A GB0208384D0 (en) | 2002-04-11 | 2002-04-11 | Novel compounds |
| PCT/EP2003/001304 WO2003084915A1 (en) | 2002-04-11 | 2003-02-10 | Novel thyroid receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005522476A JP2005522476A (ja) | 2005-07-28 |
| JP2005522476A5 true JP2005522476A5 (https=) | 2006-03-30 |
Family
ID=9934685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003582114A Pending JP2005522476A (ja) | 2002-04-11 | 2003-02-10 | 新規甲状腺受容体リガンド |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050171104A1 (https=) |
| EP (1) | EP1492756A1 (https=) |
| JP (1) | JP2005522476A (https=) |
| KR (1) | KR20040102080A (https=) |
| CN (1) | CN1324001C (https=) |
| AU (1) | AU2003210234A1 (https=) |
| CA (1) | CA2481976A1 (https=) |
| GB (1) | GB0208384D0 (https=) |
| IL (1) | IL164406A0 (https=) |
| WO (1) | WO2003084915A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501223B2 (en) | 2003-06-20 | 2013-08-06 | Hill's Pet Nutrition, Inc. | Methods for dietary management of cats to avoid hyperthyroidism |
| WO2006128058A2 (en) | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| CN1882327A (zh) | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| EP1849465A4 (en) * | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR |
| CN101374420B (zh) * | 2006-01-26 | 2016-11-09 | 希尔氏宠物营养品公司 | 治疗猫科动物的甲状腺机能亢进的方法和组合物 |
| BRPI0713634A2 (pt) * | 2006-07-03 | 2012-10-23 | Hills Pet Nutrition Inc | uso de iodo ou selênio, composição e kit para prevenir e/ou tratar uma doença cardiovascular em um felino com hipertiroidismo, e, meio para comunicar informação |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| US8039484B2 (en) * | 2006-10-31 | 2011-10-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| TWI534144B (zh) | 2009-04-20 | 2016-05-21 | 田邊三菱製藥股份有限公司 | 甲狀腺荷爾蒙β受體作動藥 |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CN105237381A (zh) * | 2015-10-14 | 2016-01-13 | 湖南华腾制药有限公司 | 5-羟基-1-茚酮的制备方法 |
| CN105330525A (zh) * | 2015-10-25 | 2016-02-17 | 湖南华腾制药有限公司 | 7-羟基-1-茚酮的制备方法 |
| CA3044059A1 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| US11707472B2 (en) | 2017-06-05 | 2023-07-25 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| CA3075877A1 (en) | 2017-09-14 | 2019-03-21 | Riken | Method for producing retinal tissues |
| CN107929273A (zh) * | 2017-12-01 | 2018-04-20 | 崔坤元 | 肝脏靶向药物 |
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| KR20210138639A (ko) | 2019-03-13 | 2021-11-19 | 다이니뽄 스미토모 세이야쿠 가부시키가이샤 | 이식용 신경 망막의 품질을 평가하는 방법 및 이식용 신경 망막 시트 |
| CA3194226A1 (en) | 2020-09-11 | 2022-03-17 | Riken | Complex containing neural retina-containing cell aggregates and matrix, and method for manufacturing same |
| EP4201428A4 (en) | 2020-09-11 | 2024-09-11 | Sumitomo Pharma Co., Ltd. | MEDIUM FOR TISSUE INTENDED FOR TRANSPLANTATION |
| WO2023090427A1 (ja) | 2021-11-19 | 2023-05-25 | 国立研究開発法人理化学研究所 | シート状網膜組織の製造方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9713739D0 (en) * | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
| GB9828442D0 (en) * | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| GB9927056D0 (en) * | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| CZ20022771A3 (cs) * | 2000-02-17 | 2003-09-17 | Bristol-Myers Squibb Company | Ligandy thyreoidního receptoru odvozené od anilinu |
| GB0015205D0 (en) * | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
| GB0111861D0 (en) * | 2001-05-15 | 2001-07-04 | Karobio Ab | Novel compounds |
-
2002
- 2002-04-11 GB GBGB0208384.8A patent/GB0208384D0/en not_active Ceased
-
2003
- 2003-02-10 JP JP2003582114A patent/JP2005522476A/ja active Pending
- 2003-02-10 CA CA002481976A patent/CA2481976A1/en not_active Abandoned
- 2003-02-10 CN CNB038099373A patent/CN1324001C/zh not_active Expired - Fee Related
- 2003-02-10 KR KR10-2004-7016192A patent/KR20040102080A/ko not_active Withdrawn
- 2003-02-10 EP EP03745755A patent/EP1492756A1/en not_active Withdrawn
- 2003-02-10 US US10/510,645 patent/US20050171104A1/en not_active Abandoned
- 2003-02-10 AU AU2003210234A patent/AU2003210234A1/en not_active Abandoned
- 2003-02-10 WO PCT/EP2003/001304 patent/WO2003084915A1/en not_active Ceased
-
2004
- 2004-02-10 IL IL16440604A patent/IL164406A0/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005522476A5 (https=) | ||
| DE02735262T1 (de) | Schilddrüsenhormon-rezeptor-antagonisten zur behandlung von herzerkrankungen & metabolischen störungen | |
| JP2004533450A5 (https=) | ||
| JP2013536855A5 (https=) | ||
| JP2007502806A5 (https=) | ||
| JP2004529174A5 (https=) | ||
| PT1614418E (pt) | Utilização de derivados do ácido (-)(3-tri-halometilfenoxi) (4- halofenil) acético para o tratamento de hiperuricemia | |
| RU2005138592A (ru) | Производные пропионовой кислоты, полезные в лечении липидных расстройств | |
| JP2004534825A5 (https=) | ||
| EP2089023A2 (en) | Methods of treating neuropathic pain with agonists of ppar-gamma | |
| JP2005522476A (ja) | 新規甲状腺受容体リガンド | |
| ZA200302517B (en) | Peroxisome proliferator activated receptor alpha agonists. | |
| PT1458369E (pt) | Gel compreendendo pelo menos um retinóide e peróxido de benzoílo | |
| RU2007116317A (ru) | Гексафторизопропанол-замещенные производные простых эфиров | |
| JP2005521721A5 (https=) | ||
| EP0915823B1 (fr) | Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations | |
| JP2015508068A5 (https=) | ||
| EP2464349A2 (en) | Use of ppar delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases | |
| JP2005532331A5 (https=) | ||
| RU2005109163A (ru) | НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPARα И PPARγ | |
| JP2020504120A5 (https=) | ||
| JP2005513014A5 (https=) | ||
| WO1998034909A1 (fr) | Composes biaromatiques, compositions les contenant et utilisations | |
| JP2004506037A5 (https=) | ||
| EP0986537B1 (fr) | Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant |